(Q35871904)

10 August 2017

1 reference

title

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? (English)

1 reference

10 August 2017

1 reference

Carolyn F Deacon

1

0 references

Jens Juul Holst

object named as

Jens J Holst

series ordinal

3

0 references

Bo Ahrén

series ordinal

2

object named as

Bo Ahrén

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1091-1102

1 reference

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Autonomic regulation of islet hormone secretion--implications for health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1091

10.1517/13543784.13.9.1091

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference